Abbreviations
- CML::
-
Chronic myeloid leukemia
- GIST::
-
Gastrointestinal stromal tumor
- IM::
-
Imatinib mesylate
References
Johnson JR, Bross P, Cohen M, Rothmann, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R (2003) Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 9:1972–1979
Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. The Oncologist 9:271–281
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantajian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, Nagai T, Mori M, Komatsu N, Ozawa K (2004) Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its concentration with clinical outcomes. Leukemia Lymphoma 45:2349–2351
Novartis (2006) Gleevec® (Imatinib mesylate).www.gleevec. com. Cited 2006
Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Serizawa H, Ebihara Y (2004) Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16:2160–2161
Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen GUKM, Staten AM, Pazdur R (2002) Approval Summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935–942
Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, Soiffer RJ (2003) Fatal hepatic necrosis following imatinib mesylate therapy. Blood 102:3455–3456
James C, Trouette H, Marit G, Cony-Makhoul P, Mahon F-X (2003) Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 17:978–979
Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF (2005) Imatinib (Gleevec®)-induced hepatotoxicity. J Cin Gastroenterol 39:75–77
Consult MD (2005) Celecoxib. www. mdconsult.com. Cited 2005
Acknowledgments
Dr. Ayse Leyla Mindikoglu was supported by the 2004 American Association for the Study of Liver Diseases (AASLD) Advanced Hepatology Fellowship Award.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mindikoglu, A.L., Regev, A., Bejarano, P.A. et al. Imatinib Mesylate (Gleevec) Hepatotoxicity. Dig Dis Sci 52, 598–601 (2007). https://doi.org/10.1007/s10620-006-9117-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9117-1